Indene Compounds Selective Ras Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Ras-driven cancers and related diseases lack effective therapeutic options, as existing drugs fail to selectively target abnormal Ras proteins without harming normal cells, and there is a need for novel compounds that can inhibit Ras-dependent diseases.
Innovation Solution
Development of novel indene-related compounds with specific chemical structures that selectively inhibit Ras proteins, potentially offering improved antitumor properties and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drugs are used to treat Ras-driven cancers, then general cancer treatment is provided, but selective inhibition of abnormal Ras proteins without harming normal cells is not achieved
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target abnormal Ras proteins through selective binding to unique structural features of mutant Ras, such as the p12 conformation or specific mutation sites (G12C, G12V, etc.). The indene and indane core structures are configured to interact with specific regions of the Ras protein that differ between normal and mutant forms, enabling selective inhibition of cancer cells while sparing normal cells with wild-type Ras.
Solution Approach 2:
The patent employs parameter changes by systematically modifying chemical parameters of the core structures (indene, indane, azaindene, azaindane) including substituent positions, ring configurations, and molecular weight to optimize selectivity. The compounds are designed with specific molecular weights (300-700 Da) and hydrophobicity parameters to enhance binding affinity for mutant Ras while maintaining cell permeability and reducing off-target effects.
2Reliability
If Ras-selective drugs are developed to target mutant Ras specifically, then highly efficacious treatments with minimized toxicity are achieved, but the complexity of identifying and optimizing selective compounds increases
Solution Approach 1:
The patent applies segmentation by dividing the Ras protein target into distinct functional regions and designing separate compound series that target specific regions. Different core structures (indene, indane, azaindene, azaindane) are developed to target different mutant types or different binding sites on Ras, allowing systematic optimization of selectivity for each mutant subtype rather than attempting a single universal inhibitor.
Solution Approach 2:
The patent employs universality by creating a platform of core structures (indene, indane, azaindene, azaindane) that can be systematically modified to target multiple Ras mutants. The core scaffolds are designed to accommodate various substituents that can be optimized for different mutation types (G12C, G12V, G13D, etc.), providing a universal approach to targeting diverse Ras-driven cancers with a family of related compounds rather than requiring entirely separate drug discovery programs for each mutant.
3Power
If compounds with high binding affinity for Ras substrate GTP are designed, then potent Ras inhibition is achieved, but selectivity between abnormal and normal Ras proteins is reduced
Solution Approach 1:
The patent applies the intermediary principle by using the unique p12 conformation of certain Ras mutants as an intermediate binding state. The compounds are designed to stabilize or bind preferentially to this intermediate conformation that is more accessible in mutant Ras than in normal Ras, serving as a mediator that enables selective high-affinity binding to mutant forms without requiring direct competition with GTP at the canonical binding site.
Data Source
AI summary
Disclosed are compounds for medical uses, for example, compounds of formula Ia,wherein A1, A2, A3, A4, A5, A6, A7, R6, R7 and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.